BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kageyama T, Komori M, Miyamoto K, Ozaki A, Suenaga T, Takahashi R, Kusunoki S, Matsumoto S, Kondo T. Combination of cyclosporine A with corticosteroids is effective for the treatment of neuromyelitis optica. J Neurol 2013;260:627-34. [PMID: 23076828 DOI: 10.1007/s00415-012-6692-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Chen H, Zhang Y, Shi Z, Feng H, Yao S, Xie J, Zhou H. The Efficacy and Tolerability of Mycophenolate Mofetil in Treating Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder in Western China. Clinical Neuropharmacology 2016;39:81-7. [DOI: 10.1097/wnf.0000000000000131] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
2 Giovannelli J, Ciron J, Cohen M, Kim HJ, Kim SH, Stellmann JP, Kleiter I, McCreary M, Greenberg BM, Deschamps R, Audoin B, Maillart E, Papeix C, Collongues N, Bourre B, Laplaud D, Ayrignac X, Durand-Dubief F, Ruet A, Vukusic S, Marignier R, Dauchet L, Zephir H; NEMOS (Neuromyelitis Optica Study Group in Germany), NOMADMUS (Neuromyelitis Optica study Group in France), OFSEP (Observatoire Français de la Sclérose en Plaques) investigators. A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica. Ann Clin Transl Neurol 2021;8:2025-37. [PMID: 34505407 DOI: 10.1002/acn3.51451] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Kitley J, Palace J. Therapeutic options in neuromyelitis optica spectrum disorders. Expert Review of Neurotherapeutics 2016;16:319-29. [DOI: 10.1586/14737175.2016.1150178] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
4 Warne J, Pryce G, Hill JM, Shi X, Lennerås F, Puentes F, Kip M, Hilditch L, Walker P, Simone MI, Chan AW, Towers GJ, Coker AR, Duchen MR, Szabadkai G, Baker D, Selwood DL. Selective Inhibition of the Mitochondrial Permeability Transition Pore Protects against Neurodegeneration in Experimental Multiple Sclerosis. J Biol Chem 2016;291:4356-73. [PMID: 26679998 DOI: 10.1074/jbc.M115.700385] [Cited by in Crossref: 42] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
5 Sato DK, Lana-peixoto MA, Fujihara K, de Seze J. Clinical Spectrum and Treatment of Neuromyelitis Optica Spectrum Disorders: Evolution and Current Status: Clinical Spectrum and Treatment of NMO/NMOSD. Brain Pathology 2013;23:647-60. [DOI: 10.1111/bpa.12087] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
6 Kleiter I, Gold R. Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders. Neurotherapeutics 2016;13:70-83. [PMID: 26597098 DOI: 10.1007/s13311-015-0400-8] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 9.3] [Reference Citation Analysis]
7 Huang W, Wang L, Zhang B, Zhou L, Zhang T, Quan C. Effectiveness and tolerability of immunosuppressants and monoclonal antibodies in preventive treatment of neuromyelitis optica spectrum disorders: A systematic review and network meta-analysis. Mult Scler Relat Disord 2019;35:246-52. [PMID: 31425902 DOI: 10.1016/j.msard.2019.08.009] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
8 Duchow A, Paul F, Bellmann-strobl J. Current and emerging biologics for the treatment of neuromyelitis optica spectrum disorders. Expert Opinion on Biological Therapy 2020;20:1061-72. [DOI: 10.1080/14712598.2020.1749259] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
9 Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O, Kümpfel T. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol. 2014;261:1-16. [PMID: 24272588 DOI: 10.1007/s00415-013-7169-7] [Cited by in Crossref: 325] [Cited by in F6Publishing: 278] [Article Influence: 36.1] [Reference Citation Analysis]
10 Noval S, Oreja-Guevara C, Contreras I. Monitoring neuromyelitis optica activity. Expert Rev Neurother 2013;13:989-99. [PMID: 24053343 DOI: 10.1586/14737175.2013.832850] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Huang TL, Lin KH, Wang JK, Tsai RK. Treatment strategies for neuromyelitis optica. Ci Ji Yi Xue Za Zhi 2018;30:204-8. [PMID: 30305782 DOI: 10.4103/tcmj.tcmj_102_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Vodopivec I, Matiello M, Prasad S. Treatment of neuromyelitis optica. Curr Opin Ophthalmol 2015;26:476-83. [PMID: 26367088 DOI: 10.1097/ICU.0000000000000202] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
13 Holmøy T, Høglund RA, Illes Z, Myhr KM, Torkildsen Ø. Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder. J Neurol 2020. [PMID: 33011853 DOI: 10.1007/s00415-020-10235-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
14 Duchow A, Chien C, Paul F, Bellmann-Strobl J. Emerging drugs for the treatment of neuromyelitis optica. Expert Opin Emerg Drugs 2020;25:285-97. [PMID: 32731771 DOI: 10.1080/14728214.2020.1803828] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
15 Waliszewska-Prosół M, Chojdak-Łukasiewicz J, Budrewicz S, Pokryszko-Dragan A. Neuromyelitis Optica Spectrum Disorder Treatment-Current and Future Prospects. Int J Mol Sci 2021;22:2801. [PMID: 33802046 DOI: 10.3390/ijms22062801] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Yao X, Su T, Verkman AS. Clobetasol promotes remyelination in a mouse model of neuromyelitis optica. Acta Neuropathol Commun 2016;4:42. [PMID: 27117475 DOI: 10.1186/s40478-016-0309-4] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
17 . Cyclosporine A and azathioprine are effective adjunctive treatments for neuromyelitis optica. Nat Rev Neurol 2012;8:659-659. [DOI: 10.1038/nrneurol.2012.235] [Reference Citation Analysis]
18 Mori S, Kurimoto T, Murai Y, Ueda K, Sakamoto M, Chihara N, Yamada-Nakanishi Y, Nakamura M. Efficacy for the Annual Relapse Rate after the Immunosuppressive Therapy in Patients Associated with Anti-AQP4 or Anti-MOG Antibody-Positive Optic Neuritis. J Ophthalmol 2020;2020:8871146. [PMID: 33628473 DOI: 10.1155/2020/8871146] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Papadopoulos MC, Bennett JL, Verkman AS. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol. 2014;10:493-506. [PMID: 25112508 DOI: 10.1038/nrneurol.2014.141] [Cited by in Crossref: 148] [Cited by in F6Publishing: 135] [Article Influence: 18.5] [Reference Citation Analysis]
20 Tradtrantip L, Felix CM, Spirig R, Morelli AB, Verkman AS. Recombinant IgG1 Fc hexamers block cytotoxicity and pathological changes in experimental in vitro and rat models of neuromyelitis optica. Neuropharmacology 2018;133:345-53. [PMID: 29428821 DOI: 10.1016/j.neuropharm.2018.02.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
21 Hinson SR, Lennon VA, Pittock SJ. Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders. Handb Clin Neurol. 2016;133:377-403. [PMID: 27112688 DOI: 10.1016/b978-0-444-63432-0.00021-9] [Cited by in Crossref: 36] [Cited by in F6Publishing: 20] [Article Influence: 7.2] [Reference Citation Analysis]
22 Weber KP, Straumann D. Neuro-ophthalmology update. J Neurol 2014;261:1251-6. [PMID: 24068370 DOI: 10.1007/s00415-013-7105-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
23 Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurol 2014;13:83-99. [PMID: 24331795 DOI: 10.1016/S1474-4422(13)70259-X] [Cited by in Crossref: 277] [Cited by in F6Publishing: 115] [Article Influence: 34.6] [Reference Citation Analysis]
24 Barhate KS, Ganeshan M, Singhal BS. A clinical and radiological profile of neuromyelitis optica and spectrum disorders in an Indian cohort. Ann Indian Acad Neurol 2014;17:77-81. [PMID: 24753665 DOI: 10.4103/0972-2327.128559] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
25 Takai Y, Kuroda H, Misu T, Akaishi T, Nakashima I, Takahashi T, Nishiyama S, Fujihara K, Aoki M. Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy. Mult Scler Relat Disord 2021;49:102750. [PMID: 33524925 DOI: 10.1016/j.msard.2021.102750] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Chan KH, Lee CY. Treatment of Neuromyelitis Optica Spectrum Disorders. Int J Mol Sci 2021;22:8638. [PMID: 34445343 DOI: 10.3390/ijms22168638] [Reference Citation Analysis]
27 Bienia B, Balabanov R. Immunotherapy of neuromyelitis optica. Autoimmune Dis 2013;2013:741490. [PMID: 24455211 DOI: 10.1155/2013/741490] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
28 Flanagan EP, Weinshenker BG. Neuromyelitis Optica Spectrum Disorders. Curr Neurol Neurosci Rep 2014;14. [DOI: 10.1007/s11910-014-0483-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
29 Kojima M, Oji S, Tanaka S, Izaki S, Hashimoto B, Fukaura H, Nomura K. Tacrolimus is effective for neuromyelitis optica spectrum disorders with or without anti-AQP4 antibody. Multiple Sclerosis and Related Disorders 2020;39:101907. [DOI: 10.1016/j.msard.2019.101907] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
30 Cree BA. Placebo controlled trials in neuromyelitis optica are needed and ethical. Mult Scler Relat Disord 2015;4:536-45. [PMID: 26590660 DOI: 10.1016/j.msard.2015.07.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]